ANIX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ANIX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Anixa Biosciences's share price for the quarter that ended in Jan. 2024 was $4.54. Anixa Biosciences's Shares Outstanding (EOP) for the quarter that ended in Jan. 2024 was 31.75 Mil. Therefore, Anixa Biosciences's market cap for the quarter that ended in Jan. 2024 was $144.16 Mil.
Anixa Biosciences's quarterly market cap declined from Jul. 2023 ($111.35 Mil) to Oct. 2023 ($98.42 Mil) but then increased from Oct. 2023 ($98.42 Mil) to Jan. 2024 ($144.16 Mil).
Anixa Biosciences's annual market cap increased from Oct. 2021 ($143.34 Mil) to Oct. 2022 ($173.12 Mil) but then declined from Oct. 2022 ($173.12 Mil) to Oct. 2023 ($98.42 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Anixa Biosciences's Enterprise Value for Today is $73.12 Mil.
The historical data trend for Anixa Biosciences's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anixa Biosciences Annual Data | |||||||||||||||||||||
Trend | Oct14 | Oct15 | Oct16 | Oct17 | Oct18 | Oct19 | Oct20 | Oct21 | Oct22 | Oct23 | |||||||||||
Market Cap | Get a 7-Day Free Trial | 78.68 | 49.95 | 143.34 | 173.12 | 98.42 |
Anixa Biosciences Quarterly Data | ||||||||||||||||||||
Apr19 | Jul19 | Oct19 | Jan20 | Apr20 | Jul20 | Oct20 | Jan21 | Apr21 | Jul21 | Oct21 | Jan22 | Apr22 | Jul22 | Oct22 | Jan23 | Apr23 | Jul23 | Oct23 | Jan24 | |
Market Cap | Get a 7-Day Free Trial | 135.13 | 126.31 | 111.35 | 98.42 | 144.16 |
For the Biotechnology subindustry, Anixa Biosciences's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Anixa Biosciences's Market Cap distribution charts can be found below:
* The bar in red indicates where Anixa Biosciences's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Anixa Biosciences's Market Cap for the fiscal year that ended in Oct. 2023 is calculated as
Market Cap (A: Oct. 2023 ) | = | Share Price (A: Oct. 2023 ) | * | Shares Outstanding (EOP) (A: Oct. 2023 ) |
= | $3.16 | * | 31.1452 | |
= | $98.42 |
Anixa Biosciences's Market Cap for the quarter that ended in Jan. 2024 is calculated as
Market Cap (Q: Jan. 2024 ) | = | Share Price (Q: Jan. 2024 ) | * | Shares Outstanding (EOP) (Q: Jan. 2024 ) |
= | $4.54 | * | 31.7544 | |
= | $144.16 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anixa Biosciences (NAS:ANIX) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Thank you for viewing the detailed overview of Anixa Biosciences's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Amit Kumar | director, officer: Chief Executive Officer | C/O ACACIA RESEARCH CORPORATION, 500 NEWPORT CENTER DRIVE, 7TH FLOOR, NEWPORT BEACH CA 92660 |
Michael Catelani | officer: COO & CFO | 12100 WILSHIRE BOULEVARD, SUITE 1275, LOS ANGELES CA 90025 |
Titterton Lewis H Jr | director | 6 AUTUMN LANE, SARATOGA SPRINGS NY 12866 |
Arnold M Baskies | director | 1235 SEQUOIA ROAD, CHERRY HILL NJ 08003 |
Emily Gottschalk | director | 3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE CA 95118 |
John J Monahan | director | |
David Cavalier | director | C/O AEOLUS PHARMACEUTICALS, INC., 23811 INVERNESS PLACE, LAGUNA NIGUEL CA 92677 |
Richard H Williams | director | C/O QUOKKA SPORTS INC, 525 BRANNAN ST GROUND FL, SAN FRANCISCO CA 94108 |
Dale Fox | director | 929 NOWITA PLACE, VENICE CA 90291 |
Andrea Belz | director | 1011 ALTA VISTA DRIVE, ALTADENA CA 91001 |
Tisha Stender | officer: Chief Operating Officer | 900 WALT WHITMAN ROAD, MELVILLE NY 11747 |
Robert Andrew Berman | officer: President and CEO | C/O ITUS CORPORATION, 12100 WILSHIRE BOULEVARD, SUITE 1275, LOS ANGELES CA 90025 |
John H. Roop | officer: Sr. Vice President-Engineering | C/O COPYTELE, INC., 900 WALT WHITMAN ROAD, MELVILLE NY 11747 |
Bruce F Johnson | director | 20 S. WACKER DR, CHICAGO IL 60606 |
Kent B. Williams | director | C/O COPYTELE INC., 900 WALT WHITMAN ROAD, MELVILLE NY 11747 |
From GuruFocus
By PRNewswire • 11-27-2023
By PRNewswire PRNewswire • 10-31-2022
By PRNewswire PRNewswire • 08-31-2022
By PRNewswire PRNewswire • 11-08-2022
By PRNewswire PRNewswire • 12-19-2022
By PRNewswire • 08-28-2023
By PRNewswire PRNewswire • 02-27-2023
By PRNewswire • 01-10-2024
By PRNewswire PRNewswire • 04-17-2023
By PRNewswire • 12-07-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.